We are live on ! Find out more
CALA

Calithera Biosciences

Delisted

CALA was delisted on the 1st of February, 2023.

28 hedge funds and large institutions have $4.44M invested in Calithera Biosciences in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

18.47% less ownership

Funds ownership: 54.47% → 36% (-18%)

48% less funds holding

Funds holding: 54 → 28 (-26)

50% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 14

81% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 32

82% less capital inflows, than outflows

Capital inflows: $604K | Capital outflows: $3.3M

Holders
28
Holders Change
-26
Holders Change %
-48.15%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
7
Reduced
14
Closed
32
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CALA Hedge Fund Activity: Q2 2022 in Review

28 of the 5,965 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences (CALA) for Q2 2022, worth a combined $4.44M — down 75% from $18M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of CALA and 6 opened new positions — a net loss of 26 holders — while 14 trimmed existing stakes and 7 added.

The largest buyer was Acadian Asset Management, adding an estimated $261K. The largest seller was Primecap Management, cutting an estimated $539K.

  • 28 institutional investors held Calithera Biosciences (CALA) as of Q2 2022, down from 54 in Q1 2022.
  • Funds reported $4.44M of Calithera Biosciences stock for Q2 2022, down 75% quarter-over-quarter.
  • 6 funds opened new Calithera Biosciences positions in Q2 2022 and 32 closed out, a net change of -26 holders.
  • The largest Calithera Biosciences buyer in Q2 2022 was Acadian Asset Management, an estimated $261K added.
  • The largest Calithera Biosciences seller in Q2 2022 was Primecap Management, an estimated $539K sold.

Based on aggregated 13F filings for Q2 2022.